$EXEL shares starting to break-out.FDA decision scheduled to Nov. 29. "optimists like cabozantinib's chances for approval" says Motley Fool. Looks like negative over-all market conditions weighing in on the stock move. Watch this one!
www.fool.com/investi...this-week-in-th.aspx
www.fool.com/investi...this-week-in-th.aspx